Search Results

MLPs at the EOC: Dynamics of Feature Learning

• Authors : Terjék, Dávid

Subjects: Computer Science - Machine Learning; 68T07

Record details

MLPs at the EOC: Concentration of the NTK

• Authors : Terjék, Dávid; González-Sánchez, Diego

Subjects: Computer Science - Machine Learning; Statistics - Machine Learning; 68T07

Record details

MLPs at the EOC: Spectrum of the NTK

• Authors : Terjék, Dávid; González-Sánchez, Diego

Subjects: Computer Science - Machine Learning; 68T07

Record details

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

• Source: Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (cohort A) or in Combination with Durvalumab (cohort B) Prior to Primary Debulking Surgery in

Record details

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

• Authors : Merck KGaA, Darmstadt, Germany

• Source: An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant

Record details

NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro.

• Authors : Lee, Kevin J.¹ (AUTHOR) ; Chokshi, Sagar^1,2 (AUTHOR); Joshi, Tanvi^1,3 (AUTHOR)

Subjects: *OVARIAN epithelial cancer; *DNA repair; *CYTOTOXINS

• Source: International Journal of Molecular Sciences. Feb2025, Vol. 26 Issue 4, p1719. 13p.

Record details

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

• Authors : European Network of Gynaecological Oncological Trial Groups (ENGOT); Gynecologic Oncology Group

• Source: A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced

Record details

IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (IMPACT)

• Source: IMPACT: A Phase 0 Randomized Window-of-Opportunity Study of Novel and Repurposed Therapeutic Agents in Women Triaged to Primary Surgery for Advanced Epithelial Ovarian Cancer in Stages IIIa - IV.

Record details

The INFLUENCE of Cytoreduction on PRO in EOC (INFLUENCE)

• Authors : Helse Stavanger HF; Sorlandet Hospital HF

• Source: The INFLUENCE of Cytoreduction on Patient Reported Outcomes in Patients With Epithelial Ovarian Cancer

Record details

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

• Source: Prehabilitation for Elderly Patients With Advanced Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy

Record details